Table 2.

The demographics, clinical characteristics and outcomes of IMH stratified by resolution

	No resolution of IMH (n = 11)	Resolution of IMH (n = 10)	p-value
Age (years)	59 (10)	62 (11)	0.64
Gender (female)	6 (55%)	7 (70%)	0.66
Race			0.67
Asian	0 (0%)	1 (10%)
Black or African American	2 (18%)	2 (20%)
Hispanic	0 (0%)	1 (10%)
White or Caucasian	9 (82%)	6 (60%)
History of autoimmune disease	0 (0%)	1 (10%)	0.48
BMI at referral	26 (24–30)	28 (26–31)	0.36
Tumor type			0.016
Bladder	2 (18%)	0 (0%)
Breast	4 (36%)	0 (0%)
Esophageal	0 (0%)	2 (20%)
GBM	1 (9%)	1 (10%)
Gastric	0 (0%)	2 (20%)
Liposarcoma	0 (0%)	1 (10%)
Melanoma	2 (18%)	1 (10%)
NSCLC	0 (0%)	3 (30%)
Ovarian	1 (9%)	0 (0%)
Pancreatic	1 (9%)	0 (0%)
Metastatic	4 (36%)	3 (30%)	1.00
Type of immunotherapy			0.59
CTLA-4	2 (18%)	0 (0%)
CTLA-4 PD-1/PD-L1	1 (9%)	2 (20%)
PD-1/PD-L1	8 (73%)	8 (80%)
ANA titer (> 1:80)	2 (25%)	4 (44%)	0.62
ASMA titer (> 1:40)	1 (11%)	1 (14%)	1.00
Doses of ICI before IMH	2 (1–4)	4 (2–9)	0.32
Time from first ICI to IMH referral (days)	84 (44–238)	107 (44–200)	0.89
Toxicity at referral			1.00
Grade 1–2	3 (27%)	3 (30%)
Grade 3–4	8 (73%)	7 (70%)
Pattern of injury			0.30
Hepatocellular	3 (27%)	4 (40%)
Mixed	2 (18%)	4 (40%)
Cholestatic	6 (55%)	2 (20%)
Toxicity at peak			0.15
Grade 1–2	1 (9%)	4 (40%)
Grade 3–4	10 (91%)	6 (60%)
Pattern of injury			1.00
Hepatocellular	3 (27%)	3 (30%)
Mixed	4 (36%)	4 (40%)
Cholestatic	4 (36%)	3 (30%)
Toxicity 1 week after treatment			0.041
Grade 1–2	1 (13%)	6 (75%)
Grade 3–4	7 (88%)	2 (25%)
Treatment with steroid	9 (82%)	8 (80%)	1.00
Initial dosing of steroids > 1 mg/kg/day prednisone equivalent	5 (56%)	4 (50%)	1.00
Duration of steroid (days)	28 (12–58)	110 (46–162)	0.074
Time from referral to death (days)	33 (10–67)	467 (412–472)	0.016
Death at follow-up	11 (100%)	3 (30%)	0.001

n (%), mean (STD), median (IQR)